Rewriting the Rules on Multiple Myeloma Resistance: Ajai Chari, MD

Why It Matters

Understanding resistance and early cure signals reshapes treatment planning, potentially extending survival and reducing the need for continual therapy cycles in multiple myeloma.

Key Takeaways

• Resistance driven by disease burden, high‑risk genetics, extramedullary spread
• Repeated BCMA targeting can diminish antigen expression, reducing efficacy
• CARTITUDE‑4 shows CAR‑T therapy extending progression‑free survival
• MajesTEC‑3 early data suggest durable responses with bispecific antibodies
• Intelligent sequencing remains uncertain without reliable predictors of relapse

Pulse Analysis

Multiple myeloma has long been treated as a chronic, inevitably relapsing disease, prompting clinicians to plan for multiple lines of therapy. Recent advances—CAR‑T cells, bispecific antibodies, and antibody‑drug conjugates—have dramatically deepened responses, shifting the conversation toward the possibility of long‑term disease control. By questioning the assumption of universal relapse, experts like Dr. Ajai Chari are prompting a reassessment of treatment goals, moving from merely extending life to aiming for functional cure.

The biological underpinnings of resistance are now better defined. High tumor burden and high‑risk cytogenetics accelerate disease progression, while extramedullary involvement signals aggressive biology. Crucially, repeated targeting of B‑cell maturation antigen (BCMA) can lead to antigen down‑regulation, blunting the efficacy of both CAR‑T and bispecific platforms. Early-phase trials such as CARTITUDE‑4, which reported extended progression‑free survival with BCMA‑directed CAR‑T, and MajesTEC‑3, showing sustained responses with a BCMA bispecific, suggest that a subset of patients may achieve durable remissions that approximate cure.

These insights create both opportunity and uncertainty for clinicians. Without robust biomarkers to predict which patients will sustain remission, sequencing remains a gamble: should a potent CAR‑T be reserved for later lines, or deployed early to maximize depth of response? The field is racing to develop predictive assays—genomic signatures, minimal residual disease metrics, and antigen density assessments—to guide personalized sequencing. As data mature, the paradigm may shift from reactive treatment to proactive, biomarker‑driven strategies, ultimately redefining the standard of care for multiple myeloma patients worldwide.